Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 3/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.34 |
| ▸ | TPSAB1 | Q15661 | 3/20 | 0.34 |
| ▸ | TPSD1 | Q9BZJ3 | 3/20 | 0.34 |
| ▸ | TPSG1 | Q9NRR2 | 3/20 | 0.34 |
| ▸ | NR1H4 | Q96RI1 | 4/20 | 0.32 |
| ▸ | PLG | P00747 | 4/20 | 0.31 |
| ▸ | DRD3 | P35462 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7069828 | 0.93 | TPSAB1 (0.37) | F10NPC1HDAC6TPSAB1TPSD1 | |
| SCHEMBL7069756 | 0.89 | TPSAB1 (0.34) | NPC1TPSAB1TPSD1TPSG1NR1H4 | |
| SCHEMBL7072446 | 0.84 | LMNA (0.41) | NPC1TPSAB1TPSD1TPSG1POLB | |
| SCHEMBL7068659 | 0.82 | NPC1 (0.36) | F10NPC1TPSAB1TPSD1TPSG1 | |
| SCHEMBL7073159 | 0.81 | TP53 (0.36) | PLG | |
| SCHEMBL7069832 | 0.81 | TPSAB1 (0.34) | NPC1TPSAB1TPSD1TPSG1DRD3 | |
| SCHEMBL7071905 | 0.80 | TPSAB1 (0.33) | NPC1TPSAB1TPSD1TPSG1NR1H4 | |
| SCHEMBL7075194 | 0.79 | ACSS2 (0.36) | POLB | |
| SCHEMBL7067706 | 0.79 | TPSAB1 (0.34) | NPC1TPSAB1TPSD1TPSG1DRD3 | |
| SCHEMBL7068430 | 0.78 | NPC1 (0.35) | NPC1TPSAB1TPSD1TPSG1NR1H4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030212120-A1 | Compositions comprising a substituted benzimidazole useful for treating immunomediated inflammatory disorders | AXYS PHARMACEUTICALS, INC. (US) | 2003-11-13 | — | — | US | disclosed |
| US-6562854-B2 | Antiinflammatory agents; respiratory system disorders | AXYS PHARMACEUTICALS, INC. | 2003-05-13 | — | — | US | disclosed |
| US-20010053779-A1 | Novel compounds and compositions for treating diseases asociated with protease activity | Celera Corporation | 2001-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010053779-A1 | Novel compounds and compositions for treating diseases asociated with protease activity | CMA1, CPA3, TPSG1 | F10 1801/4885NPC1 1362/4885HDAC6 379/4885 |
| US-20030212120-A1 | Compositions comprising a substituted benzimidazole useful for treating immunomediated inflammatory disorders | CMA1, TPSG1, TPSD1 | F10 3661/4885NPC1 3932/4885HDAC6 709/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.